, Volume 39, Issue 1, pp 243–247 | Cite as

Effects of Acetylsalicylic Acid Usage on Inflammatory and Oxidative Stress Markers in Hemodialysis Patients

  • Fabíola Pansani Maniglia
  • José Abrão Cardeal da Costa


The aims of this study were to determine the effects of acetylsalicylic acid (ASA) on inflammation and oxidative stress markers in hemodialysis (HD) patients and to examine the associations between these markers and the sociodemographic and clinical characteristics of participants. The study included 36 subjects who used 300 mg of ASA for 60 days. Inflammation and oxidative stress were assessed based on levels of biochemical markers. ASA usage promoted a decrease in high-sensitivity C-reactive protein (p = 0.01). The level of hydrogen peroxide increased after 30 days of use of ASA and subsequently decreased (p = 0.01). Reduced glutathione reduced at the end of the study (p < 0.01); the malondialdehyde level did not change and the levels of vitamins A and E were inverse to drug use (p = 0.01). ASA usage promoted reduced levels of inflammation, increased production of markers of oxidative stress, and reduced antioxidant defense.


hemodialysis acetylsalicylic acid inflammation oxidative stress antioxidant vitamins 



We are grateful to Paula Garcia Chiarello, Alceu Afonso Jordão Júnior, and Paula Payão Ovidio for valuable discussions about this research, and we acknowledge financial support from CAPES-Brazil (Coordination for the Improvement of Higher Education Personnel—Brazil).

Conflict of Interest

The authors declare that they have no competing interests.


  1. 1.
    Jofré, R., P. Rodriguez-Benitez, J.M. López-Gómez, and R. Pérez-Garcia. 2006. Inflammatory syndrome in patients on hemodialysis. Journal of the American Society of Nephrology 17: 274–280.CrossRefGoogle Scholar
  2. 2.
    Ajala, M.O., P.S. Ogunro, and A. Odun. 2011. Effect of hemodialysis on total antioxidant status of chronic renal failure patients in government hospitals in Lagos Nigeria. Nigerian Journal of Clinical Practice 14: 154–158.CrossRefPubMedGoogle Scholar
  3. 3.
    Vecchi, A.F., F. Bamonti, C. Novembrino, et al. 2009. Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients. Nephrology, Dialysis, Transplantation 24: 2524–2529.CrossRefPubMedGoogle Scholar
  4. 4.
    Abahusain, M.A., and N.N. Al-Nahedh. 2002. The biochemical status of vitamin A and alpha-tocopherol during different stages of renal disease and its relationship to diabetes. Saudi Journal of Kidney Diseases and Transplantation 13: 18–23.PubMedGoogle Scholar
  5. 5.
    Santangelo, F., V. Witko-Sarsat, T. Drüeke, and B. Descamps-Latscha. 2004. Restoring glutathione as a therapeutic strategy in chronic kidney disease. Nephrology, Dialysis, Transplantation 19: 1951–1955.CrossRefPubMedGoogle Scholar
  6. 6.
    Montazerifar, F., M. Hashemi, M. Karajibani, and M. Dikshit. 2010. Hemodialysis alters lipid profiles, total antioxidant capacity, and vitamins A, E, and C concentrations in humans. Journal of Medicinal Food 13: 1490–1493.CrossRefPubMedGoogle Scholar
  7. 7.
    Menon, V., T. Greene, X. Wang, et al. 2005. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney International 68: 766–772.CrossRefPubMedGoogle Scholar
  8. 8.
    Bergstrom, J., and B. Lindholm. 1998. Malnutrition, cardiac disease, and mortality: an integrated point of view. American Journal of Kidney Diseases 32: 834–841.CrossRefPubMedGoogle Scholar
  9. 9.
    Zyga, S., C.A. Hutchison, S. Stringer, et al. 2014. Inflammation and endothelial dysfunction in the initiation and propagation of cardiovascular disease in patients with chronic kidney disease. British Journal of Medical Research 4: 2568–2580.CrossRefGoogle Scholar
  10. 10.
    Sundaram, S.P.M., S. Nagarajan, and A.J.M. Devi. 2014. Chronic kidney disease—effect of oxidative stress. Chinese Journal of Biology 2014: 1–6.CrossRefGoogle Scholar
  11. 11.
    Wali, R.K. 2010. Aspirin and the prevention of cardiovascular disease in chronic kidney disease. Journal of the American College of Cardiology 56: 966–968.CrossRefPubMedGoogle Scholar
  12. 12.
    Sociedade Brasileira de Cardiologia. 2013. Diretrizes brasileiras de antiagregantes plaquetários e anticoagulantes em cardiologia. Arquivos Brasileiros de Cardiologia 101: 1–95.CrossRefGoogle Scholar
  13. 13.
    Antiplatelet Trialists’ Collaboration. 1994. Bulário Eletrônico: Aspirina [internet]. Brasília: Ministério da Saúde. Agência Nacional de Vigilância Sanitária (ANVISA) 2009. British Medical Journal 308: 81-106. Available at:[25345-1-0].PDF [Date accessed: 7 January 2013]
  14. 14.
    Kalantar-Zadeh, K., J.D. Kopple, G. Block, and M.H. Humphreys. 2001. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. American Journal of Kidney Diseases 38: 1251–1263.CrossRefPubMedGoogle Scholar
  15. 15.
    Roberts, W.L., R. Sedrick, L. Moulton, A. Spencer, and N. Rifai. 2000. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clinical Chemistry 46: 461–468.PubMedGoogle Scholar
  16. 16.
    Södergren, E. et al. 1998. Re-evaluation of the ferrous oxidation in xylenol orange assay for the measurement of plasma lipid hydroperoxides. Journal of Biochemical and Biophysical Methods 37: 137–146.Google Scholar
  17. 17.
    Nourooz-Zadeh, J., J. Tajaddini-Sarmadi, and S.P. Wolff. 1994. Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Analytical Biochemistry 220: 403–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Galli, F., M. Piroddi, C. Annetti, C. Aisa, E. Floridi, and A. Floridi. 2005. Oxidative stress and reactive oxygen species. Contributions to Nephrology 149: 240–60.CrossRefPubMedGoogle Scholar
  19. 19.
    Gerard-Monnier, D., I. Erdelmeier, K. Régnard, N. Moze-Henry, J.C. Yadan, and J. Chaudière. 1998. Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation. Chemical Research in Toxicology 11: 1176–83.CrossRefPubMedGoogle Scholar
  20. 20.
    Ellman, G.L. 1959. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 82: 70–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Hu, M.L. 1994. Measurement of protein thiol groups and glutathione in plasma. Methods in Enzymology 233: 380–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Arnaud, J., I. Fortis, S. Blachier, D. Kia, and A. Favier. 1991. Simultaneous determination of retinol, alpha-tocopherol and beta-carotene in serum by isocratic high-performance liquid chromatography. Journal of Chromatography 572: 103–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Huang, Y., Y. Zhong, X. Ding, et al. 2011. Aspirin can reduce serum C reactive protein level in maintenance hemodialysis patients. Chinical Journal of Nephrology 27: 271–275.Google Scholar
  24. 24.
    Waterman, M., B. Fuhrman, S. Keidar, and T. Hayek. 2009. Aspirin promotes low density lipoprotein susceptibility to oxidative modification in healthy volunteers. The Israel Medical Association Journal 11: 730–734.PubMedGoogle Scholar
  25. 25.
    Selvakumar, C., U. Maheshwari, X. Suganthi, and X. Archana. 2012. Oxidant-antioxidant disturbance in men classified as obese according to the preliminary WHO guidelines for Asians. Journal of Stress Physiology & Biochemistry 8: 172–181.Google Scholar
  26. 26.
    Steer, K.A., T.M. Wallace, C.H. Bolton, and M. Hartog. 1997. Aspirin protects low density lipoprotein from oxidative modification. Heart 77: 333–337.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Kirkova, M., E. Ivancheva, and E. Russanov. 1994. In vitro effects of aspirin on malondialdehyde formation and on activity of antioxidant and some metal-containing enzymes. Comparative Biochemistry and Physiology. Pharmacology, Toxicology and Endocrinology 108: 145–52.CrossRefPubMedGoogle Scholar
  28. 28.
    Young, D.S. 1987. Implementation of SI units for clinical laboratory data. Annals of Internal Medicine 106: 114–129.CrossRefPubMedGoogle Scholar
  29. 29.
    Espe, K.M., J. Raila, A. Henze, et al. 2011. Impact of vitamin A on clinical outcomes in haemodialysis patients. Nephrology, Dialysis, Transplantation 26: 4054–4061.CrossRefPubMedGoogle Scholar
  30. 30.
    Podhaisky, H.P., A. Abate, T. Polte, S. Oberle, and H. Schröder. 1997. Aspirin protects endothelial cells from oxidative stress: possible synergism with vitamin E. FEBS Letters 417: 349–351.CrossRefPubMedGoogle Scholar
  31. 31.
    Espe, K.M., J. Raila, A. Henze, et al. 2013. Low plasma a-tocopherol concentrations and adverse clinical outcomes in diabetic hemodialysis patients. Clinical Journal of the American Society of Nephrology 8: 1–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Fabíola Pansani Maniglia
    • 1
  • José Abrão Cardeal da Costa
    • 1
  1. 1.Division of Nephrology, Ribeirão Preto Medical School of University of São PauloRibeirão PretoBrazil

Personalised recommendations